enGene Holdings (NASDAQ: ENGN) assigns new directors to key board committees

Rhea-AI Filing Summary

enGene Holdings Inc. updated a prior report to clarify board committee assignments for two recently appointed directors. Effective October 2, 2025, the board named Philip Astley-Sparke to the Audit Committee and the Nominating and Corporate Governance Committee. Michael Heffernan was appointed to the Audit Committee and the Compensation Committee.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

0001980845true00-000000000019808452025-07-072025-07-070001980845us-gaap:WarrantMember2025-07-072025-07-070001980845us-gaap:CommonStockMember2025-07-072025-07-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 07, 2025

enGene Holdings Inc.

(Exact name of Registrant as Specified in Its Charter)

British Columbia			001-41854	Not applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4868 Rue Levy, Suite 220
Saint-Laurent, Quebec, Canada				H4R 2P1
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 514 332-4888

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		ENGN		The Nasdaq Stock Market LLC
Warrants, each exercisable for one Common Share, at an exercise price of $11.50 per Share		ENGNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 8, 2025, enGene Holdings Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) disclosing that, on and effective as of July 8, 2025, the Board of Directors of the Company (the “Board”) appointed Messrs. Philip Astley-Sparke and Michael Heffernan to the Board as directors. At the time of the filing of the Original Form 8-K, committee assignments for these directors had not been determined.

The Company is filing this Amendment to the Original Form 8-K to disclose that, on and effective as of October 2, 2025, the Board appointed Mr. Astley-Sparke to serve as a member of each of the Audit Committee and the Nominating and Corporate Governance Committee of the Board, and appointed Mr. Heffernan to serve as a member of each of the Audit Committee and the Compensation Committee of the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ENGENE HOLDINGS INC.
Date:	October 2, 2025	By:	/s/ Ronald H.W. Cooper
			Name: Ronald H.W. Cooper Title: Chief Executive Officer

FAQ

What change did enGene Holdings Inc. (ENGN) report in this 8-K/A?

enGene Holdings Inc. reported updated committee assignments for two directors. The filing clarifies which board committees Philip Astley-Sparke and Michael Heffernan joined, information that was not specified in the company’s earlier report regarding their initial board appointments.

Which board committees did Philip Astley-Sparke join at enGene (ENGN)?

Philip Astley-Sparke was appointed to the Audit Committee and the Nominating and Corporate Governance Committee. These roles give him responsibilities in overseeing financial reporting processes and helping shape board composition and corporate governance practices at enGene Holdings Inc.

Which board committees did Michael Heffernan join at enGene Holdings (ENGN)?

Michael Heffernan was appointed to the Audit Committee and the Compensation Committee. This places him in roles overseeing financial reporting oversight and executive and director pay matters, aligning his responsibilities with key financial and compensation governance functions at the company.

When were the new committee assignments at enGene Holdings (ENGN) made effective?

The committee assignments for Philip Astley-Sparke and Michael Heffernan were effective October 2, 2025. The company’s board approved these changes on that date, and the amendment formally documents and discloses the updated roles for both directors.

Why did enGene (ENGN) file an amendment instead of a new report?

The company filed an amendment because the original report already disclosed the directors’ appointments but did not specify their committee assignments. This 8-K/A simply updates that earlier disclosure to add the missing committee role information for both directors.